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Abstract
Background: We evaluated pneumococcal colonization in children and adults between the 
time of 7-valent pneumococcal conjugate vaccine (PCV) introduction in the immunization 
program in April 2009 to two years after transitioning to 13-valent PCV in 2011.   
Methods: Community-based pneumococcal carriage surveillance was undertaken between 
May-November 2013 (Period-3; n=1884), with similar surveys in 2009 (Period-1, n=2010) 
and 2011 (Period-2; n=3659). Households with children below two years had a similar 
probability of being sampled in all surveys. Nasopharyngeal swabs were processed using 
standard methods and serotyped by Quellung. 
Results: In children >9-59 months of age, overall pneumococcal colonization prevalence 
declined from 81.8% in Period-1 to 65.0% in Period-3 (p<0.001). Reductions of 70% 
(95%CI: 60%-77%; 41.2% vs. 13.6%) in PCV7-serotypes colonization and 66% 
(95%CI:48%-78%; 15.3% vs. 4.4%) for the six additional PCV-serotypes in PCV13 (PCV13-
add6VT) were observed. There was, however, high residual prevalence of colonization by 
PCV7-serotypes 19F (14.9% vs. 6.3%) and 23F (8.5% vs. 4.1%), despite reduction of 57% 
(95%CI:35%-80%) and 52% (95%CI:21%-83%), respectively. Among individuals >12 years 
of age, there was 61% (95%CI:18%-82%) reduction in PCV7-serotype colonization (3.1% vs. 
1.3%; ) and 75% (95%CI: 11%-93%) decrease for PCV13-add6VT (2.1% vs. 0.6%) between 
Period-1 and Period-3. 
Conclusions: The residual prevalence of serotypes 19F and 23F in PCV-immunized and -
unvaccinated age-groups, four years after introducing PCV in the South African public 
immunization program, suggests ongoing community transmission and transient vaccine 
effects. 
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1. Introduction
Pneumococcal conjugate vaccine (PCV) immunization of children reduces their risk of 
Streptococcus pneumoniae (pneumococcus) vaccine-serotype nasopharyngeal acquisition and 
disease 1,2. Since young children are the major source of transmission of pneumococci in the 
community 3,4, childhood PCV immunization has also reduced the prevalence of vaccine-
serotype colonization among unvaccinated age groups 2,5-7. Although there has been near 
elimination of PCV-serotype colonization and invasive disease in some high-income 
countries following childhood PCV immunization 8,9, there are limited data from low-middle 
income countries 10,11, including from settings with high prevalence of HIV infection. 
Monitoring the prevalence of pneumococcal vaccine-serotype colonization, a pre-requisite for 
developing pneumococcal disease 12, is a potential metric for assessing the indirect effect of 
childhood PCV-immunization against vaccine-serotype pneumococcal disease in older, non-
immunized age-groups 1.    
The 7-valent PCV (PCV7) was introduced in the South African public immunization program 
in April 2009, using a 6, 14 and 40 weeks of age dosing schedule; with no catch-up campaign 
of older children. In May 2011, the immunization program transitioned to 13-valent PCV 
(PCV13), with a limited catch-up campaign for children less than 36 months (m.) of age and 
in those 36-71m. with underlying medical conditions. We previously reported, in a rural 
setting with high HIV prevalence, within two years of PCV7 introduction and when PCV 
coverage in children was modest (52%), a 50-64% reduction in PCV7-serotype colonization 
prevalence in age-groups targeted and not targeted for PCV immunization 13.
The aim of this study was to evaluate the prevalence of vaccine-serotype and non-vaccine 
serotype (NVT) pneumococcal nasopharyngeal colonization in children (>9-59m. and 60-
144m. age) and household members older than 12 years (y.) of age in a rural African setting, 
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two years following transitioning from PCV7 to PCV13 in the infant public immunization 
program.  
2.0 Methods
2.1 Study population and study methods
This community-based study was undertaken in Agincourt sub-district, a health-socio 
demographic surveillance site (HDSS) in Mpumalanga province, South Africa. The 
pneumococcal colonization survey performed from May to November 2013 (Period-3) was 
preceded by two earlier cross-sectional surveys approximating the same calendar months in 
2009 (Period-1) and 2011 (Period-2) as described 13. Aside from children <9m. not being 
enrolled during Period-1, the sampling strategy and methodology was similar across the three 
surveillance periods 13. Briefly, households with children aged ≤24m. were identified from 
the HDSS database as potential participants. A random list of villages was generated and 
households with children less than two years old were selected until the required sample size 
was achieved. A total of 9, 26 and 19 villages were selected in 2009, 2011 and 2013, 
respectively. All 9 villages included in 2009 were also included in 2011, and 16 villages 
selected in 2011 were also included in sampling during to 2013. Households were included if, 
in addition to the listed child, there was at least one individual >12y. who agreed to study-
participation. Although the same household could have been randomly selected in any of the 
three sampling periods, the same child would generally have contributed to an older child 
age-group stratum. 
A questionnaire was administered at the time of nasopharyngeal swab collection. HIV status 
was based on self-reporting in the first two study-periods. In Period-3, HIV testing following 
counselling was offered to individuals older than 18y. HIV testing was not undertaken in the 
younger age-group due to an anticipated low HIV prevalence in individuals aged <18y, and 
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consequently we relied on self-reporting by parents/care-givers for HIV-infection status for 
these individuals. This was premised on the successful roll-out of the mother-to-child HIV 
prevention program between 2008 and 2011, following which the mother-to-child HIV 
transmission rates declined from 9.6% to 2.3%.14 
The sample collection and laboratory testing methods for culture of bacteria, including 
Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus, were as 
previously reported 13,15. Briefly, nasopharyngeal swabs were performed in all subjects using 
an aluminum shafted, Dacron swab (MW and E, Medical Wire and Equipment Co. Ltd., 
Corsham, Wiltshire, England), in addition to which an oropharyngeal swab was collected 
from those older than 12y. Samples were processed at the Centre for Respiratory Diseases 
and Meningitis (CRDM) at the National Institute for Communicable Diseases, South Africa, 
by routine microbiological methodologies. Serotyping was undertaken by the Quellung 
method using factor and serotype-specific antisera (Statens Serum Institute, Copenhagen, 
Denmark). Presumptive pneumococcal presenting no phenotypically detectable capsule  were 
categorized as non-typeable, once pneumococcal identification was confirmed with lytA PCR. 
Where >1 distinct morphological colony type was present, each colony was serotyped. 
Serotypes 6A, 6B, 6C and 6D were distinguished only using the relevant antisera and without 
any additional molecular typing.
2.2 Sample size calculation
The sample size for Period-3 was based on providing 80% power to detect a 30% reduction in 
PCV13-no-PCV7 serotypes, i.e. PCV13-additional six serotypes (PCV13-add6VT) 
colonization among individuals >12y. age (referred to as “adults” henceforth) relative to the 
1.1% prevalence documented in 2011. This required enrolment of 900 adults. We estimated 
that to enroll 900 adults, we would require visiting at least 450 households with at least one 
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child aged <24m. Based on PCV13-add6VT colonization prevalence of 15.2% in 2011 
among children aged <24m., the enrolled number of children <24m. age (n=434) would 
provide 80% power to detect at least a 40% reduction in prevalence of PCV13-add6VT 
colonization in this age-group.
2.3 Statistical analysis
Multiple, simultaneous colonization by different serotypes in the same individual were 
considered as independent events when measuring the prevalence of colonization if they 
differed in stratification into PCV7-serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), PCV13-
add6VT (1, 3, 5, 6A, 7F and 19A) or non-vaccine serotypes (i.e. any other pneumococcal 
serotype including non-typeable isolates). Comparison of the prevalence of serotype-specific 
pneumococcal colonization between Period-3 and Period-1 were calculated using  or 𝜒2
Fisher’s exact test where appropriate. Serotype-specific analysis was not adjusted for any 
potential confounders. Log-binomial regression models with the log link function were used 
to estimate the risk ratios for pneumococcal carriage in Period-3 compared to Period-1, 
adjusting for potential confounding factors such as age, gender, fuel used for cooking in the 
household, presence of a child attending day care and household structure. Statistical analyses 
were conducted using SAS version 9.4 (SAS Institute, Inc., NC).
2.4 Ethics
The study was approved by the Human Research Ethics Committee (Medical, M130461) at 
the University of the Witwatersrand and the Mpumalanga Department of Health Ethics 
Committee. Informed written consent was obtained from participants ≥18y. old, and 
parental/guardian consent was obtained for younger participants. In addition, those aged 8-
17y. provided verbal assent for study participation.
3.0 Results
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We enrolled 2010 (from 577 households), 3659 (1079 households) and 1884 (563 
households) individuals in 2009 (Period-1), 2011 (Period-2) and 2013 (Period-3), 
respectively; as detailed in Table 1. Differences in demographic characteristics in Period-3 
compared to Period-1 included fewer individuals per household (mean 5.6 vs. 8.8; p<0.001), 
including fewer children ≤5y. age (mean 1.5 vs. 1.8; p=0.014). Also, households were less 
likely to use coal/wood for cooking (43.8% vs. 69.9%), and conversely more likely to use 
electricity (55.8% vs. 28.2%; p<0.001); Table 1. Children were less likely to ever have been 
breastfed in Period-3 (82.5%) compared to Period-1 (92.0%; p<0.001); albeit similar in the 
12-24m. age-group (81.8% vs. 85.7%). Children were less likely to be on antibiotics at time 
of sampling in Period-3 (1.5%) than Period-1 (7.7%; p=0.002). The prevalence of parental-
reported HIV-positivity in their children was comparable across the study periods (3.0 to 
3.2%). None of the children were immunized in Period-1. In Period-3, 65.2% of children 3-
9m. age received at least two PCV doses; and 82.2% of those >9-24m. received at least three 
PCV doses, as did 49.8% in the 24-59m. age-group; Table 1. None of the older children (60-
144m.) were immunized with PCV in any of the three periods.
Among the adults (>12y. age), the mean age was lower in Period-3 (31.8y.) than Period-1 
(33.3y.; p=0.040), albeit unlikely to be of clinical significance. The prevalence of self-
reported HIV-positivity was higher in Period-3 (22.0%) than Period-1 (7.9%; p<0.001), 
including those >18y. age (8.3% vs. 23.4%). Among adults >18y. old who consented for HIV 
testing in Period-3 (n=456), the HIV-positivity prevalence was 20.2% (n=92); including 
being positive in 100% (n=50) of those who self-reported to be HIV-infected, and positive in 
a further 36 individuals who self-reported to be HIV-uninfected. Of the self-reported HIV-
infected individuals, 55.3% and 70.8% were on antiretroviral therapy in Period-1 and Period-
3, respectively. Generally, there was a low prevalence of smoking (1.7 to 2.2%), sniffing of 
tobacco (2.0 to 2.7%) or alcohol use (6.4% to 10.5%) across the study-periods. A higher 
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percentage of individuals in Period-3 (19.3%) than Period-1 (13.9%; p=0.002) had an 
underlying chronic medical illness, and 0.9 to 1.0% were on treatment for tuberculosis; Table 
1.  
3.1 Overall prevalence of pneumococcal colonization  
Across all age-groups, the prevalence of overall pneumococcal colonization was lower in 
Period-3 (35.8%) than Period-1 (42.4%; adjusted risk ratio [aRR]: 0.81, p <0.001); Table 2 
and Figure 1. This included lower prevalence in Period-3 compared to Period-1 in children 
aged >9m-59m. (65.0% vs. 81.8%; aRR: 0.81, p<0.001) who were eligible to have been 
vaccinated by Period-3, as well as in the PCV-naïve 60-144m. age-group (51.8% vs. 60.0%; 
aRR: 0.82, p=0.03); Table 2.   
In individuals >12y. age, overall prevalence of pneumococcal colonization did not differ 
between Period-3 (10.6%) and Period-1 (11.3%); although a significant reduction was 
observed in the >12-18y age group (22.8% vs. 15.3%; aRR: 0.58, p=0.04); Table 2. This was 
in contrast to our previous observation of reduction in overall pneumococcal colonization in 
the >12y. age-group between Period-1 (11.3%) and Period-2 (6.8%; aRR: 0.53); including in 
the >12-18y. (22.8% vs. 12.3%; aRR: 0.51) and >18-45y. (10.7% vs. 5.8%; aRR:0.44) age-
groups. 
3.2 Prevalence of PCV7-serotype colonization  
Overall prevalence of PCV7-serotype colonization declined by 66.0% (95% CI: 56% - 73%) 
between Period-1 (18.3%) and Period-3 (6.8%); including further reduction from Period-2 
(11.4%) to Period-3 (aRR: 0.58, p<0.001). The lower prevalence of PCV7-serotype 
colonization in Period-3 (13.6%) compared to Period-1 (41.2%; aRR: 0.30, p<0.001) among 
children >9-59m. age, was evident in the >9-23m. (13.4% vs. 45.1%; aRR: 0.26, p<0.001) 
and 24-59m. (14.7% vs. 35.5%; aRR: 0.37, p<0.001) age-groups. There was also a 41% (95% 
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CI: 2% - 64%) reduction of PCV7-serotyope colonization in Period-3 (10%) compared 
Period-1 (19.0%) in the PCV-naïve 60-144m. age-group.  
There was 61% (95% CI: 18% - 82%) lower prevalence of PCV7-serotype colonization in the 
>12y. age-group in Period-3 (1.3%) compared to Period-1 (3.1%); although no further 
significant decline was observed between Period-2 (1.2%) and Period-3 (aRR: 0.86, p=0.73). 
Reductions in PCV7-colonization from Period-1 to Period-3 were detected in the 18-45y. 
(3.0% vs. 1.0%; aRR: 0.21, p=0.02) age-group, whilst the reduction in the 12-18y. age-group 
(5.7% vs. 3.4%; aRR: 0.64, p=0.42) was not significant; Table 2. 
4.3 Prevalence of PCV13 additional-6 serotypes colonization
Overall and across specific age-groups, the prevalence of PCV13-add6VT colonization was 
similar in Period-1 and Period-2; Table 2. Within two-years of transitioning from PCV7 to 
PCV13, the overall prevalence of PCV13-add6VT colonization declined by 66% (95% CI: 
51% - 77%) (Period-1 7.9% vs. Period-3 2.8%). The reduction in PCV13-add6VT 
colonization was evident across all age-groups (albeit not analyzable for >45y. age). In those 
>9-59m. age, PCV13-add6VT colonization decreased by 66% (95% CI: 48%-78%), from 
15.3% in Period-1 to 4.4% in Period-3; including reductions in the >9-23m. (72% (95% CI: 
50% - 84%)) and 24-59m. (60% (95% CI: 24% - 79%)) age-groups. A 59% (95% CI: 19% - 
80%) reduction in PCV13-add6VT colonization was also observed in Period-3 (5.6%) 
compared to Period-1 (11.0%) in the PCV-naïve 60-144m. age-group.
Likewise, the prevalence of PCV13-add6VT colonization was 75% (95% CI: 11% - 93%) 
lower in the >12y. age-group in Period-3 (0.6%) compared to Period-1 (2.1%); including 
89% (95% CI: 4% - 99%) reduction in the 12-18y. (1.1% vs. 5.7%) and 73% (95% CI: 12% - 
91%) decline in the 18-45y. age-group (0.7% vs. 1.9%); Figure 1 and Table 2.
3.4 Prevalence of non-PCV13 serotype colonization
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Although the overall prevalence of NVT colonization was similar between Period-1 (18.4%) 
and Period-2 (19.3%; aRR: 1.06, p=0.44), it increased to 26.8% by Period-3 (aRR: 1.49, 
p<0.001). The increase in NVT colonization in Period-3 (47.8%) compared to Period-1 
(29.5%, aRR: 1.84, p<0.001) was evident for children >9-59m. age, including 2.06 (95% CI: 
1.63 – 2.61) and 1.60 (95% CI: 1.24 – 2.07) adjusted-fold increases in the >9-23m. (48.5% 
vs. 27.1%, <0.001) and 24-59m. (49% vs. 33%, p=0.003) age-groups, respectively. There 
was no change in NVT colonization in the 60-144m. age-group (33.2% in Period-1 vs. 37.2% 
in Period-3, p=0.78).   
Among individuals >12y. age although there was an initial decrease in NVT colonization 
between Period-1 (6.6%) and Period-2 (4.7%; aRR: 0.57, p=0.004); there was a 113% (95% 
CI: 47% - 212%) increase in NVT colonization by Period-3 (8.9%) compared to Period-2. 
Although the prevalence of NVT in Period-3 was slightly higher than in Period-1, this was 
not significant (aRR: 1.18, p=0.37); Table 2. 
3.5 Serotype-specific colonization by age-group
Reductions in prevalence of PCV13-serotype colonization were observed for most serotypes 
with ≥1.5% prevalence in Period-1 (except 9V) in the >9-59m. age-group, with similar 
observations when stratified by >9-23m. and 24-59m. age; Table 3. In the >9-59m. age-
group, this included reduction in colonization prevalence between Period-1 and Period-3 for 
serotypes 6B (84.6%, p<0.001), 14 (95.4%,p<0.001), 18C (86.7%, p=0.007), 19F (57.7%, 
p<0.001), 23F (51.8%; p=0.001), 6A (83.1%; p<0.001) and 19A (56.5%; p=0.007); Table 3. 
There, however, remained a prominent residual colonization prevalence in Period-3 of PCV7 
(13.6%) and PCV13-add6VT (4.4%), with the dominant vaccine-serotypes including 19F 
(6.3%), 23F (4.1%), 19A (2.0%), 6B (1.7%) and 6A (1.5%), which were also the top-five 
PCV13 colonizing serotypes in Period-1 (14.9%, 8.5%, 4.6%, 10.1% and 8.9%, respectively); 
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Table 3. Furthermore, significant increases in NVT colonization between Period-1 and 
Period-3 in the >9-59m. age-group included serotypes 15A (0.6% vs. 2.4%; p=0.006), 16F 
(0.7% vs. 5.6%; p<0.001), 21 (0.1% vs. 1.7%; p=0.003), 34 (2.7% vs. 6.8%; p<0.001) and 
35B (0.6% vs. 4.7%; p<0.001). 
In the PCV-naïve 60-144m. age-group, although significant reductions were observed for 
colonization by vaccine-serotypes 4 (100%; p=0.007) and 6A (91.1%, p=0.003), there were 
no reductions between Period-1 and Period-3 for serotypes 19F (4.2% vs. 4.1%), 23F (4.5% 
vs. 3.2%) and 3 (3.9% vs 3.6%); Table 3. The only NVT to show a significant increase in the 
60-144m. age-group in Period-3 compared to Period-1 was 35B (4.8% vs 0.3%; p<0.001).
In the >12y. age-group, the prevalence of PCV13-serotype colonization in Period-1 was <1% 
for all serotypes (except serotype 3), and although trending to lower prevalence in Period-3, 
the differences were not statistically significant. For serotype 3, the colonization prevalence 
declined to 0.2% in Period-3 compared to 1.0% in Period-1 (p=0.030). Significant increases 
in NVT colonization in Period-3 compared to Period-1 in the >12y. age-group were evident 
for serotypes 8 (0.6% vs. 0%; p=0.01) and 35B (1.4% vs. 0%; p<0.001); Table 3. 
3.6 Association of HIV infection and pneumococcal colonization
There were very few children <12y. age in Period-3 (n=15) that were HIV-infected based on 
self-reporting, hence, limiting any comparisons on whether differences in colonization 
prevalence existed by HIV-status. For individuals >18y. age with self-reported HIV-status, 
there was a higher prevalence of PCV7-serotype colonization in those living with (2.5%) 
compared to those without HIV (0.4%; p=0.010), albeit not evident when limited to 
analyzing those in whom HIV testing was done; Table 4. Also, there were no differences for 
overall, PCV13-add6VT or NVT colonization in adults living with and without HIV; Table 4.
4. Discussion
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In this study, undertaken in a rural, low-income African setting with high prevalence of adults 
living with HIV, immunization of children with a two dose primary series (6 and 14 weeks of 
age) and a booster dose at 40 weeks of age, was associated with rapid decline in colonization 
by PCV7 and PCV13-add6VT serotypes in the age-groups targeted for vaccination as well as 
in older-children (60-144m.) and among adolescents/adults (>12y.) who were naïve for any 
pneumococcal vaccination. Notably, the reductions in PCV7 and PCV13-add6VT 
colonization in the vaccine-naïve groups (>60m. age) occurred within two years of 
introduction of PCV7 and PCV13, respectively, into the public immunization program. 
Additionally, although NVT colonization increased by almost 50%, complete replacement of 
carriage by NVT was not yet realized in this community.   
Sizeable vaccine indirect effects were observed, with the  percentage reduction in PCV7 and 
PCV13-add6VT colonization in Period-3 compared to Period-1 in the 60-144m. been 41% 
and 59%, respectively; and 61% and 75%, respectively in the >12y. age-group. These point-
estimates (albeit overlap of the 95%CI) were lower than the reduction in PCV7 (70%) and 
PCV13-ad6 (66%) observed in the >9-59m. age-group that were eligible for PCV-
immunization. Nonetheless, despite up-to-date vaccine coverage of 82.2% in the >9-23m. 
age-group in Period-3, there was residual colonization by PCV7-serotypes of 13% and 
PCV13-serotypes of 18% in these children and in the combined >9-59m. age-group. The 
prevalence of PCV7-serotypes being above 10% shows that there is still significant ongoing 
transmission of these serotypes in the community. These findings are in contrast to 
observations in industrialized countries where within a similar period post-PCV7 
introduction, the prevalence of vaccine-serotype colonization among children <2 years old in 
Boston, USA, was around 2% 16 and 3.6% in England 6. The absence of an initial catch-up 
campaign at vaccine introduction may have left a reservoir of PCV-serotypes among 
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unvaccinated older children, resulting in continued transmission of these types in the 
community. 
Similarly, high residual prevalence of vaccine-serotype colonization in age-groups targeted 
for vaccination, as well as in unvaccinated age-groups have been observed from other sub-
Saharan African countries, including in the presence of using different dosing schedules with 
or without catch-up campaigns. In The Gambia PCV7-serotype colonization prevalence 
among children have been observed in villages where there was no catch-up campaign 
(13.6% among children aged 2.5 to 5 years) 17 and with PCV13-serotypes at five years after 
PCV13 introduction (11.4% among 6 to 12 months old infants) using a three dose primary 
series and no booster dose (3+0 schedule)18. In rural Malawi, the reduction in PCV13-
serotype colonization in children 1-4years eligible to have been immunized with PCV13, 
declined by 63% (28.2% vs. 17.9%); and was also 67% lower in women living without HIV 
(6.6% vs. 2.4%) within four years of introducing PCV13 (3+0 schedule) into the childhood 
immunization program 19.  
The impact of catch-up campaigns in protection of at risk children against invasive 
pneumococcal disease is widely accepted 20, however, its effect on carriage has not been well 
described. In Kilifi, Kenya, where 10-valent PCV was introduced as a three-dose primary 
series coupled with a catch-up campaign through to five years of age, there was also only 
partial reduction, i.e. 74% (95%CI: 66-80) in PCV10-serotype colonization from the pre-
vaccine era (33.8% vs. 8.8%)) through to five years after introduction21.   
Although limited by sample size, in our study for those PCV13-serotypes with >1% 
colonization prevalence among the >9-59m. age-group in Period-1, the percentage reduction 
in colonization by Period-3 varied from 95% (14), 83-87% (6A, 6B and 18C), to more 
modest 38-58% (3, 23F, 19A, 19F and 9V); among the latter group, serotypes 19F and 23F 
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were the most common colonizing serotypes in Period-1. The high residual PCV13-serotype 
colonization was dominated by these two serotypes, both of which are included in PCV7 that 
was introduced into the immunization program four years before sampling was undertaken in 
Period-3. Moreover, there was no change in prevalence between Period-1 and Period-3 for 
serotype 19F (4.2% vs. 4.4%) and 23F (4.5% vs. 3.2%) colonization in the 60-144m. age-
group. The reasons for the differential impact of PCV immunization on colonization by 
different serotypes are still hypothetical. 
In the older age-groups (>12y.), contrary to the scenario in children, declines in PCV7-
serotype colonization were detected from Period-1 (3.1%) to Period-2 (1.2%) but no further 
reductions were detected by Period-3 (1.3%), suggesting that this indirect effect of childhood 
vaccination might have reached a plateau state two years after PCV7 introduction despite 
increase in vaccination coverage including in a wider age range. A dynamic transmission 
model using data from Blantyre, Malawi, suggested that the high residual vaccine serotype 
colonization levels at seven years post-PCV13 introduction was mainly due to age-related 
characteristics of the local force of infection 22. Further, the model at 10 years post-PCV13 
introduction, estimated that there would be approximately 75% reduction in PCV13-serotype 
colonization across all age-groups22. In our setting it could be that PCV coverage is still 
suboptimal for complete indirect effects to materialize in adults, leading to a lag in time 
between the effects observed in children. Another explanation could be that there exists a 
reservoir of unvaccinated age groups contributing to the ongoing transmission of some the 
PCV7-serotypes in settings such as ours, as opposed to in high-income countries where 
children 1-4 years of age are considered the main source of pneumococcal transmission. 23 A 
reduction in colonization by PCV13-add6VT was, however, detected in the >12y. age-groups 
between Period-2 and Period-3. 
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Of the individual PCV serotypes, 3 was the only serotype with a lower colonization 
prevalence in Period-3 compared to Period-1 in the >12y. age-group. Interesting, no 
significant temporal changes were noted for serotype 3 colonization among the >9-59m. and 
60-144m. age-groups, and the highest prevalence was in the 60-144m. group. These results 
suggest that the dynamics of colonization and transmission might differ for serotype 3, and 
that the reduction in older individuals may be due to temporal changes rather than indirect 
effects of childhood vaccination. Previously, we have reported that adults living with HIV 
had higher prevalence of PCV-serotype colonization, including that of serotype 3 when 
compared to HIV-uninfected individuals 13, and this was corroborated by data from Malawi 
and Uganda 24,25. In the current analysis probably due to the small number of adults 
confirmed to be HIV-infected no differences were detected.
In the >9-144m. age-group there were gradual reductions in overall pneumococcal 
colonization during the three sampling Periods despite significant increases in NVT 
colonization. In the >12y. age-group, however, after an initial decrease from Period-1 to 
Period-2, there was a rebound in the prevalence of overall pneumococcal colonization in 
Period-3 that was largely driven by the increase in prevalence of NVT colonization between 
Period-3 and Period-2. This may be explained by the fact that following vaccine introduction 
NVT colonization first established a niche in children before effective transmission to adults 
occurred. An increase in NVT colonization following an initial decrease was also observed in 
the Gambia among adults in villages vaccinated with PCV7 11. Unlike other settings such as 
the England and USA 26, serotype replacement by NVT is not yet complete and competition 
between NVT and vaccine serotypes such 19F and 23F is ongoing.  
The results of this study should be taken in the context of several limitations. First, we did not 
examine the impact of carriage of multiple serotypes simultaneously. Second, since we 
sampled during the same time period (season), we could not assess the impact of seasonal 
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trends and we cannot infer whether pneumococcal carriage patterns are similar throughout the 
year.  In addition, the improvement in socioeconomic conditions (including smaller 
household size) over time, may have influenced the dynamics of pneumococcal colonization 
and contributed to the overall reduction in pneumococcal carriage. Third, we relied on 
reported HIV status, and therefore could not assess the impact of HIV on colonization during 
the PCV13 era.
5. Conclusion
In conclusion, four years after the introduction of PCV7 and two years after transitioning to  
PCV13 in the public childhood immunization program, PCV-serotype colonization continues 
to decline in children <5 years of age. Nevertheless, the residual prevalence of PCV13-
serotype colonization in childhood age-groups eligible to have been immunized was >10% 
four years following implementation of the vaccine program, indicating ongoing circulation 
in the community. Our data indicate that the direct and indirect benefits of childhood PCV 
immunization, particularly in relation to vaccine-s rotypes 19F and 23F have not yet fully 
materialized. In addition, near complete replacement by NVT is yet to happen, suggesting 
that the impact of PCV vaccination is yet to be fully realized in this rural setting. Monitoring 
of colonization prevalence needs to continue in this setting.
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Period-2     
PCV7 era   








Number of households 577 1079 563
Total individuals in household (mean ± SD) 8.8 ± 4.1 8.8 ± 4.2 5.6± 2.3 <0.001
Children ≤ 5years (mean ± SD) 1.8 ± 1.0 2.0 ± 1.1 1.5± 0.8 0.014
Individuals 6 – 18 years (mean ± SD) 2.4 ± 1.8 2.2 ± 1.7 1.5± 1.4 <0.001
Individuals >18 years (mean ± SD) 4.6 ± 2.4 4.7 ± 2.6 2.5± 1.3 <0.001
Rooms used for sleeping (mean ± SD) 3.2 ± 1.5 3.2 ± 1.7 2.6 ± 1.3 <0.001
Households with a child that attends day care, n/N (%) 234/569 (41.1) 351/1078 (32.5) 235/555 (42.3) 0.68
Fuel used for cooking, n/N (%)
Coal/Wood 394/564 (69.9) 685/1066 (64.3) 235/535 (43.8) <0.001
Paraffin/Gas 11/564 (1.9) 17/1066 (1.6) 2/535 (0.4) 0.020
Electricity 159/564 (28.2) 364/1066 (34.1) 299/535 (55.8) <0.001
Children 144 months of age
Number of participants 982 1814 944
Female, N (%) 494 (50.3) 931 (51.3) 439 (46.5) 0.10
Overall age in months (mean ± SD) 48.4 ± 37.7) 42.0 ± 35.9) 42.5 ± 34.5)
            3 months (mean ± SD); n Not applicable 1.9 ± 0.82; 9 1.8 ± 0.81; 7
            3-9 months (mean ± SD); n Not applicable 6.8 ± 1.7; 71 6.2 ± 2.0; 23
           >9-23 months (mean ± SD); n 17.3 ± 3.9; 399 17.1 ± 4.0; 828 17.5 ± 4.1; 404
            24-59 months (mean ± SD); n 38.1 ± 11.6; 273 37.1 ± 11.4; 422 36.3 ± 11.6; 259
            60-144 months (mean ± SD); n 97.4 ± 25.0; 310 94.8 ± 24.4; 484 93.5 ± 21.8; 251
HIV-infected (self-reported), n/N (%) 5/163 (3.1) 20/625 (3.2) 15/503 (3.0) 0.96
Child ever breastfed, overall, n/N (%) 717/779 (92.0) 1181/1398 (84.5) 769/932 (82.5) <0.001
<12 months. 9/17 (52.9) 30/59 (50.9) 52/66 (78.8) 0.03
12-24 months 156/182 (85.7) 342/456 (75.0) 297/363 (81.8) 0.25
Child attending day-care, n/N (%) 378/981 (38.5) 648/1811 (35.8) 398/929 (42.8) 0.06
Child with tuberculosis, n/N (%) 3/977 (0.3) 2/1805 (0.1) 7/930 (0.8) 0.18
Child on previous TB treatment, n/N (%) 4/981 (0.4) 4/1808 (0.2) 9/920 (1.0) 0.13
Child on antibiotics, n/N (%) 38/981 (7.7) 96/1801 (5.3) 14/919 (1.5) 0.002
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Child ever hospitalised, n/N (%) 14/974 (1.4) 9/1804 (0.5) 11/931 (1.2) 0.62
Presence of a smoker in the household, n/N (%) 214/977 (21.9) 602/1770 (34.0) 173/927 (18.7) 0.08
PCV immunization status, n/N (%) 
3-9 months
zero doses 7/71 (9.9) 1/23 (4.3)
one dose 18/71 (25.4) 6/23 (26.1)
two doses 32/71 (45.1) 15/23 (65.2)
three doses 2/71 (2.8) 0/23 (0.0)
No vaccination information
Not applicable
12/71 (16.9) 1/23 (4.3)
>9-23 months
zero doses 399/399 (0) 50/828 (6.0) 13/404 (3.2)
one dose 107/828 (12.9) 8/404 (2.0)
two doses 191/828 (23.1) 25/404 (6.2)
three doses 313/828 (37.8) 332/404 (82.2)
No vaccination information 167/828 (20.2) 26/404 (6.4)
24 to 59 months
zero doses 273/273 (0.0) 205/422 (48.6) 48/259 (18.5)
one dose 17/422 (4.0) 21/259 (8.1)
two doses 30/422 (7.1) 34/259 (13.1)
three doses 34/422 (8.1) 129/259 (49.8)
No vaccination information 136/422 (32.2) 27/259 (10.4)
Participants aged >12 years(y.) of age
Number of participants 1028 1845 940
Female, N (%) 828 (80.5) 1563 (84.7) 752 (80.0) 0.76
Overall age in years (mean ± SD) 33.3 ± 16.7 32.6 ± 16.5 31.8 ± 16.0 0.040
            >12-18 years., (mean ± SD); n 15.0 ± 1.8; 158 14.9 ± 1.9; 285 14.3 ± 1.7; 177 0.001
            >18-45 years, (mean ± SD); n 28.2 ± 7.3; 633 28.3 ± 7.2; 1188 29.6 ± 6.5; 615 0.001
            >45 years, (mean ± SD); n 59.1 ± 10.3; 237 60.2 ± 10.7; 372 62.1 ± 11.4; 148 0.008
HIV-infected in those self-reporting, n/N (%) 40/504 (7.9) 135/1318 (10.2) 64/745 (22.0) <0.001
>12-18 years 0/24 (0) 1/88 (1.1) 8/79 (10.1)
18 years 40/480 (8.3) 134/1230 (10.9) 156/667 (23.4)
HIV-infected in those tested, n/N (%) 94/463 (20.36.%)
>12-18 years 2/7 (28.6)
18 years
          Not done                 Not done 
       Not done                       Not done 92/456 (20.2)
On antiretroviral therapy, n/N (%) 21/38 (55.3) 75/123 (61.0) 109/154 (70.8) 0.53
Page 22 of 28
URL: https://mc.manuscriptcentral.com/ervx   Email: IERV-peerreview@journals.tandf.co.uk





























































For Peer Review Only
3
Smoker, n/N (%) 17/994 (1.7) 26/1779 (1.5) 21/935 (2.2) 0.40
Sniffing tobacco, n/N (%) 27/993 (2.7) 39/1780 (2.2) 19/931 (2.0) 0.33
Drink alcohol, n/N (%) 104/994 (10.5) 114/1778 (6.4) 83/929 (8.9) 0.26
With chronic illness, n/N (%) 138/991 (13.9) 199/1775 (11.2) 179/927 (19.3) 0.002
On tuberculosis treatment, n/N (%) 7/792 (0.9) 10/1770 (0.6) 9/934 (1.0) 0.86
On cotrimoxazole, n/N (%)  4/35 (11.4) 8/101 (7.9) 0/54 (0.0)
 used to compare proportions between the two periods𝜒2 ―
TTEST used to compare the differences between means between two periods
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Table 2. Comparison of prevalence of all pneumococci, PCV7-serotypes, additional PCV13 serotypes and non-PCV13 serotypes by age-group in 
the three study periods









Period-1 Period-2 Period-3 Period-1 Period-2 Period-3 Period-1 Period-2 Period-3 Period-1 Period-2 Period-3 Period-1 Period-2 Period-3
All age-groups 2010 3659 1884 852 (42.4) 1341 (36.6) 675 (35.8) 368 (18.3) 418 (11.4) 129 (6.8) 159 (7.9) 272 (7.4) 53 (2.8) 369 (18.4) 705 (19.3) 502 (26.6)
AOR3 (95%CI), p-value 0.80 (0.74, 0.86), <0.001 0.34 (0.27, 0.44), <0.001 0.34 (0.23, 0.49), <0.001 1.49 (1.27, 1.74), <0.001
All age-groups 2010 3579 1854 852 (42.4) 1283 (35.8) 661 (35.7) 368 (18.3) 398 (11.1) 127 (6.9) 159 (7.9) 262 (7.3) 49 (2.6) 369 (18.4) 674 (18.8) 494 (26.6)
ARR (95%CI), p-value4 0.81 (0.75, 0.88), <0.001 0.35 (0.27, 0.45), <0.001 0.33 (0.23, 0.48), <0.001 1.51 (1.29, 1.76), <0.001
≤9 months ND5 80 (2.2) 30 (1.6) ND 58 (72.5) 14 (46.7) ND 20 (25.0) 2 (6.7) ND 10 (12.5) 4 (13.3) ND 31 (38.8) 8 (26.7)
0.61 (0.40, 0.93), 0.02 0.27 (0.05, 0.90), 0.03 1.07 (0.36, 3.16), 0.90 0.67 (0.35, 1.28). 0.23
>9-23 months 399 (19.9) 828 (22.6) 404 (21.4) 331 (83.0) 661 (79.8) 268 (66.3) 180 (45.1) 212 (25.6) 54 (13.4) 62 (15.5) 137 (16.5) 20 (5.0) 108 (27.1) 342 (41.3) 196 (48.5)
ARR (95%CI), p-value 0.79 (0.72, 0.88), <0.001 0.26 (0.19, 0.37), <0.001 0.28 (0.16, 0.50), <0.001 2.06 (1.63, 2.61), <0.001
24-59 months 273 (13.6) 422 (11.5) 259 (13.7) 219 (80.2) 307 (72.7) 175 (67.6) 97 (35.5) 121 (28.7) 38 (14.7) 41 (15) 64 (15.2) 13 (5) 90 (33) 135 (32) 127 (49)
ARR (95%CI), p-value 0.84 (0.74, 0.96), 0.009 0.37 (0.24, 0.56), <0.001 0.40 (0.21, 0.76), 0.005 1.60 (1.24, 2.07), 0.003
>9-59 months 672 (33.4) 1250 (34.2) 663 (35.2) 550 (81.8) 915 (73.2) 431 (65.0) 277 (41.2) 314 (25.1) 90 (13.6) 103 (15.3) 192 (15.4) 29 (4.4) 198 (29.5) 449 (35.9) 317 (47.8)
ARR (95%CI), p-value 0.81 (0.75, 0.89), <0.001 0.30 (0.23, 0.40), <0.001 0.34 (0.22, 0.52), <0.001 1.84 (1.54, 2.19), <0.001
60-144 months 310 (15.4) 484 (13.2) 251 (13.3) 186 (60) 242 (50) 130 (51.8) 59 (19.0) 61 (12.6) 25 (10.0) 34 (11.0) 50 (10.3) 14 (5.6) 103 (33.2) 138 (28.5) 93 (37.1)
ARR (95%CI), p-value 0.82 (0.69, 0.98), 0.03 0.59 (0.36, 0.98), 0.04 0.41 (0.20, 0.81), 0.01 1.04 (0.77, 1.41), 0.78
>9-144months 982 (48.9) 1734 (47.4) 914 (48.5) 736 (74.9) 1157 (66.7) 561 (61.4) 336 (34.2) 375 (21.6) 115 (12.6) 137 (14.0) 242 (14.0) 43 (4.7) 301 (30.7) 587 (33.9) 410 (44.9)
ARR (95%CI), p-value 0.81 (0.75, 0.88), <0.001 0.32 (0.25, 0.41), <0.001 0.35 (0.24, 0.51), <0.001 1.62 (1.38, 1.90), <0.001
>12-18 years 158 (7.9) 285 (7.8) 177 (9.4) 36 (22.8) 35 (12.3) 27 (15.3) 9 (5.7) 6 (2.1) 6 (3.4) 9 (5.7) 7 (2.5) 2 (1.1) 19 (12) 22 (7.7) 20 (11.3)
ARR (95%CI), p-value 0.58 (0.35, 0.97), 0.04 0.64 (0.22, 1.88), 0.42 0.11 (0.01, 0.96), 0.04 0.75 (0.38, 1.48), 0.41
>18-45 years 633 (31.5) 1188 (32.5) 615 (32.6) 68 (10.7) 69 (5.8) 64 (10.4) 19 (3.0) 13 (1.1) 6 (1.0) 12 (1.9) 10 (0.8) 4 (0.7) 42 (6.6) 49 (4.1) 55 (8.9)
ARR (95%CI), p-value 0.92 (0.61, 1.40), 0.70 0.21 (0.06, 0.75), 0.02 0.27 (0.09, 0.88), 0.03 1.16 (0.71, 1.88), 0.55
>45 years 237 (11.8) 372 (10.2) 148 (7.9) 12 (5.1) 22 (5.9) 9 (6.1) 4 (1.7) 4 (1.1) 0 (0.0) 1 (0.4) 3 (0.8) 0 (0.0) 7 (3) 16 (4.3) 9 (6.1)
ARR (95%CI), p-value 1.24 (0.50, 3.05), 0.65 - - 2.05 (0.78, 5.39), 0.14
>12 years 1028 (51.1) 1845 (50.4) 940 (49.9) 116 (11.3) 126 (6.8) 100 (10.6) 32 (3.1) 23 (1.2) 12 (1.3) 22 (2.1) 20 (1.1) 6 (0.6) 68 (6.6) 87 (4.7) 84 (8.9)
ARR (95%CI), p-value 0.87 (0.64, 1.18), 0.38 0.39 (0.18, 0.82), 0.01 0.25 (0.07, 0.89), 0.03 1.18 (0.82, 1.71), 0.37
1 Value in parenthesis indicate percentage of individuals in each age-group. 2Value in parenthesis indicate percentage of positive individuals. 
3ARR=adjusted risk ratio: variables adjusted for: age, gender, period, presence of a smoker in the household, fuel used for cooking and 
household structure. 4Total excludes infants ≤9 months of age. 5ND= Not done, infants ≤9 months of age were not sampled in Period-1, therefore 
comparison is for 2011 versus 2013.
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Table 3. Individual serotype prevalence by age-group in children and adults over the three study periods
Serotype Children Adults 
>9 – 23 months 24-59 months >9-59 months 60-144 months >12 years
Period-1 Period-2 Period-3 p-
value
Period-1 Period-2 Period-3 p-
value
Period-1 Period-2 Period-3 p-
value
Period-1 Period-2 Period-3 p-
value
Period-1 Period-2 Period-3 p-
value
N=399 N=828 N=404 N=273 N=422 N=259 N=672 N=1250 N=663 N=310 N=484 N=251 N=1028 N=1845 N=940
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
PCV7 serotypes
4 3 (0.8) 5 (0.6) 2 (0.5) 0.64 2 (0.7) 5 (1.2) 1 (0.4) 0.59 5 (0.7) 10 (0.8) 3 (0.5) 0.49 9 (2.9) 3 (0.6) 0 (0.0) 0.007 5 (0.5) 2 (0.1) 2 (0.2) 0.31
6B 52 (13.0) 39 (4.7) 8 (2.0) <0.001 16 (5.9) 24 (5.7) 3 (1.2) 0.003 68 (10.1) 63 (5) 11 (1.7) <0.001 13 (4.2) 10 (2.1) 5 (2.0) 0.14 5 (0.5) 3 (0.2) 3 (0.3) 0.56
9V 7 (1.8) 5 (0.6) 2 (0.5) 0.09 6 (2.2) 7 (1.7) 3 (1.2) 0.35 13 (1.9) 12 (1.0) 5 (0.8) 0.06 5 (1.6) 5 (1) 2 (0.8) 0.39 3 (0.3) 3 (0.2) 1 (0.1) 0.36
14 20 (5) 29 (3.5) 0 (0.0) <0.001 9 (3.3) 11 (2.6) 1 (0.4) 0.010 29 (4.3) 40 (3.2) 1 (0.2) <0.001 4 (1.3) 9 (1.9) 0 (0.0) 0.07 3 (0.3) 3 (0.2) 0 (0.0) 0.10
18C 5 (1.3) 1 (0.1) 1 (0.2) 0.10 5 (1.8) 3 (0.7) 0 (0.0) 0.030 10 (1.5) 4 (0.3) 1 (0.2) 0.007 1 (0.3) 2 (0.4) 1 (0.4) 0.88 4 (0.4) 1 (0.1) 0 (0.0) 0.06
19F 63 (15.8) 77 (9.3) 24 (5.9) <0.001 37 (13.6) 47 (11.1) 18 (6.9) 0.010 100 (14.9) 124 (9.9) 42 (6.3) <0.001 13 (4.2) 16 (3.3) 11 (4.4) 0.91 6 (0.6) 8 (0.4) 3 (0.3) 0.39
23F 34 (8.5) 39 (4.7) 15 (3.7) 0.004 23 (8.4) 28 (6.6) 12 (4.6) 0.08 57 (8.5) 67 (5.4) 27 (4.1) 0.001 14 (4.5) 16 (3.3) 8 (3.2) 0.42 6 (0.6) 3 (0.2) 3 (0.3) 0.39
Additional six serotypes in PCV13
1 1 (0.3) 1 (0.1) 0 (0.0) 0.31 2 (0.7) 0 (0.0) 1 (0.4) 0.59 3 (0.4) 1 (0.1) 1 (0.2) 0.32 0 (0.0) 1 (0.2) 0 (0.0) . 0 (0.0) 0 (0.0) 0 (0.0) .
3 1 (0.3) 6 (0.7) 2 (0.5) 0.57 8 (2.9) 7 (1.7) 3 (1.2) 0.15 9 (1.3) 13 (1.0) 5 (0.8) 0.29 12 (3.9) 14 (2.9) 9 (3.6) 0.86 10 (1.0) 11 (0.6) 2 (0.2) 0.030
5 0 (0.0) 0 (0.0) 0 (0.0) . 2 (0.7) 0 (0.0) 0 (0.0) 0.17 2 (0.3) 0 (0.0) 0 (0.0) 0.16 0 (0.0) 0 (0.0) 0 (0.0) . 0 (0.0) 0 (0.0) 1 (0.1) 0.30
6A 37 (9.3) 81 (9.8) 7 (1.7) <0.001 23 (8.4) 42 (10) 3 (1.2) <0.001 60 (8.9) 123 (9.8) 10 (1.5) <0.001 14 (4.5) 28 (5.8) 1 (0.4) 0.003 5 (0.5) 8 (0.4) 1 (0.1) 0.13
7F 0 (0.0) 1 (0.1) 0 (0.0) . 0 (0.0) 0 (0.0) 0 (0.0) . 0 (0.0) 1 (0.1) 0 (0.0) . 0 (0.0) 0 (0.0) 0 (0.0) . 0 (0.0) 0 (0.0) 0 (0.0) .
19A 23 (5.8) 42 (5.1) 7 (1.7) 0.003 8 (2.9) 16 (3.8) 6 (2.3) 0.66 31 (4.6) 58 (4.6) 13 (2.0) 0.007 9 (2.9) 8 (1.7) 4 (1.6) 0.31 7 (0.7) 2 (0.1) 2 (0.2) 0.12
Non-PCV13 serotypes
8 2 (0.5) 2 (0.2) 0 (0.0) 0.15 0 (0.0) 1 (0.2) 1 (0.4) 0.30 2 (0.3) 3 (0.2) 1 (0.2) 0.57 5 (1.6) 5 (1) 7 (2.8) 0.34 0 (0.0) 5 (0.3) 6 (0.6) 0.010
9N 3 (0.8) 7 (0.8) 3 (0.9) 0.99 1 (0.4) 3 (0.7) 2 (0.8) 0.53 4 (0.6) 10 (0.8) 5 (0.8) 0.72 2 (0.6) 3 (0.6) 4 (1.6) 0.28 3 (0.3) 2 (0.1) 2 (0.2) 0.73
11A 4 (1.0) 18 (2.2) 16 (4.0) 0.007 11 (4.0) 5 (1.2) 6 (2.3) 0.26 15 (2.2) 23 (1.8) 22 (3.3) 0.23 10 (3.2) 2 (0.4) 6 (2.4) 0.55 3 (0.3) 5 (0.3) 6 (0.6) 0.26
12F 3 (0.8) 3 (0.4) 1 (0.2) 0.31 0 (0.0) 1 (0.2) 0 (0.0) . 3 (0.4) 4 (0.3) 1 (0.2) 0.32 0 (0.0) 4 (0.8) 1 (0.4) 0.27 1 (0.1) 1 (0.1) 1 (0.1) 0.95
13 11 (2.8) 20 (2.4) 17 (4.2) 0.26 5 (1.8) 12 (2.8) 6 (2.3) 0.69 16 (2.4) 32 (2.6) 23 (3.5) 0.24 6 (1.9) 14 (2.9) 2 (0.8) 0.26 4 (0.4) 4 (0.2) 1 (0.1) 0.21
15A 2 (0.5) 17 (2.1) 10 (2.5) 0.020 2 (0.7) 8 (1.9) 6 (2.3) 0.13 4 (0.6) 25 (2.0) 16 (2.4) 0.006 0 (0.0) 5 (1) 3 (1.2) 0.05 1 (0.1) 6 (0.3) 2 (0.2) 0.51
15B 13 (3.3) 48 (5.8) 13 (3.2) 0.97 15 (5.5) 16 (3.8) 10 (3.9) 0.37 28 (4.2) 64 (5.1) 23 (3.5) 0.51 12 (3.9) 3 (0.6) 4 (1.6) 0.11 1 (0.1) 3 (0.2) 1 (0.1) 0.95
15C 6 (1.5) 12 (1.4) 14 (3.5) 0.07 8 (2.9) 3 (0.7) 11 (4.2) 0.41 14 (2.1) 15 (1.2) 25 (3.8) 0.07 1 (0.3) 7 (1.4) 3 (1.2) 0.22 2 (0.2) 5 (0.3) 1 (0.1) 0.62
16F 4 (1.0) 40 (4.8) 21 (5.2) 0.001 1 (0.4) 13 (3.1) 16 (6.2) <0.001 5 (0.7) 53 (4.2) 37 (5.6) <0.001 8 (2.6) 13 (2.7) 10 (4.0) 0.35 4 (0.4) 7 (0.4) 6 (0.6) 0.44
21 0 (0.0) 8 (1.0) 5 (1.2) 0.030 1 (0.4) 3 (0.7) 6 (2.3) 0.050 1 (0.1) 11 (0.9) 11 (1.7) 0.003 2 (0.6) 2 (0.4) 6 (2.4) 0.08 3 (0.3) 5 (0.3) 3 (0.3) 0.91
23A 2 (0.5) 3 (0.4) 6 (1.5) 0.16 1 (0.4) 4 (0.9) 2 (0.8) 0.53 3 (0.4) 7 (0.6) 8 (1.2) 0.12 1 (0.3) 3 (0.6) 0 (0.0) 0.37 0 (0.0) 0 (0.0) 1 (0.1) 0.30
23B 13 (3.3) 16 (1.9) 8 (2.0) 0.26 9 (3.3) 8 (1.9) 5 (1.9) 0.33 22 (3.3) 24 (1.9) 13 (2.0) 0.13 7 (2.3) 2 (0.4) 5 (2.0) 0.83 2 (0.2) 0 (0.0) 2 (0.2) 0.93
34 7 (1.8) 26 (3.1) 22 (5.4) 0.005 11 (4.0) 15 (3.6) 23 (8.9) 0.020 18 (2.7) 41 (3.3) 45 (6.8) <0.001 9 (2.9) 8 (1.7) 12 (4.8) 0.24 6 (0.6) 5 (0.3) 4 (0.4) 0.62
35B 3 (0.8) 15 (1.8) 23 (5.7) <0.001 1 (0.4) 6 (1.4) 8 (3.1) 0.010 4 (0.6) 21 (1.7) 31 (4.7) <0.001 1 (0.3) 10 (2.1) 12 (4.8) 0.001 0 (0.0) 2 (0.1) 13 (1.4) <0.001
NT 12 (3.0) 20 (2.4) 0 (0.0) <0.001 6 (2.2) 8 (1.9) 0 (0.0) 0.020 18 (2.7) 28 (2.2) 0 (0.0) <0.001 2 (0.6) 4 (0.8) 0 (0.0) 0.20 1 (0.1) 11 (0.6) 0 (0.0) 0.34
OTH 28 (7.0) 70 (8.5) 34 (8.4) 0.46 23 (8.4) 37 (8.8) 31 (12) 0.18 51 (7.6) 107 (8.6) 65 (9.8) 0.15 39 (12.6) 57 (11.8) 22 (8.8) 0.15 37 (3.6) 27 (1.5) 38 (4) 0.61
p-value from chi-squared test comparing differences in prevalence between Period-1 and Period-3. Fisher’s exact test was used for counts <5
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NT=non-typeable serotypes; OTH= all other serotypes
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Table 4. Comparison of prevalence of all pneumococci, PCV7 serotypes, additional PCV13 












Children ≤12 years self-
reporting
HIV-uninfected 488 290(59.4) 61 (12.5) 27 (5.5) 205 (42.0)
HIV-infected 15 10 (66.7) 2 (13.3) 2 (13.3) 6 (40.0)
p-value 0.79 0.92 0.20 0.88
Adults >12 years self-
reporting
HIV-uninfected 585 60 (10.3) 4 (0.7) 4 (0.7) 52 (8.9)
HIV-infected 156 14 (9.0) 3 (1.9) 1 (0.6) 10 (6.4)
p-value 0.64 0.16 0.95 0.32
Adults >18 years tested
HIV-uninfected 364 28(7.7) 0 3 (0.8) 26 (7.1)
HIV-infected 92 10 (10.9) 1 (1.1) 0 9 (9.9)
p-value 0.32 - - 0.40
Adults >18 years self-
reporting
HIV-uninfected 514 49 (9.5) 2 (0.4) 6 (1.2) 44 (8.6)
HIV-infected 157 13 (8.3) 4 (2.5) 4 (2.5) 10 (6.4)
p-value 0.64 0.01 0.21 0.38
Note that some individuals carried both vaccine and non-vaccine serotypes.
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Figure 1. Prevalence of pneumococcal colonization in children and adults in a rural South 
African setting. 
Footnote: The p-values in the panel for all ages represent the difference in prevalence in 2009 
and 2013.
Page 28 of 28
URL: https://mc.manuscriptcentral.com/ervx   Email: IERV-peerreview@journals.tandf.co.uk
Expert Review of Vaccines
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
